Literature DB >> 9307460

Axilloaxillary cardiopulmonary bypass: a practical alternative to femorofemoral bypass.

D P Bichell1, J M Balaguer, S F Aranki, G S Couper, D H Adams, R J Rizzo, J J Collins, L H Cohn.   

Abstract

BACKGROUND: Peripheral arterial and venous cannulation for cardiopulmonary bypass is used increasingly for patients undergoing minimally invasive cardiac operations, complex reoperations, or repair of aortic dissection or aneurysm, and for patients with extensive arteriosclerotic aortic disease in whom aortic cannulation is a prohibitive embolic risk. The common femoral artery and vein are most commonly used for peripheral cannulation, but these sites may be predisposed to complications, primarily because the femoral vessels are commonly involved with arteriosclerotic disease. We have recently begun to use the axillary artery and axillary vein as alternative cannulation sites, achieving full cardiopulmonary bypass, providing antegrade aortic flow, and avoiding many of the complications associated with other sites.
METHODS: Seven patients with peripheral vascular or aortic disease, or both, prohibiting safe aortic or femoral cannulation underwent cardiopulmonary bypass through axillary artery and axillary vein cannulation, approached through a small single subclavicular incision.
RESULTS: All patients were successfully cannulated and axilloaxillary cardiopulmonary bypass was possible without the need for additional cannulas. All axillary vessels were closed primarily without complication.
CONCLUSION: For an expanding population of patients with peripheral vascular and aortic disease, axilloaxillary bypass is a safe and practical alternative to aortic or femoral cannulation.

Entities:  

Mesh:

Year:  1997        PMID: 9307460     DOI: 10.1016/s0003-4975(97)00636-x

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  8 in total

1.  Right axillary arterial perfusion for a ruptured type B aortic dissection: report of a case.

Authors:  T Katoh; H Gohra; K Hamano; H Noda; Y Fujimura; N Zempo; K Esato
Journal:  Surg Today       Date:  1999       Impact factor: 2.549

Review 2.  Open and closed chest extrathoracic cannulation for cardiopulmonary bypass and extracorporeal life support: methods, indications, and outcomes.

Authors:  M L Field; B Al-Alao; N Mediratta; A Sosnowski
Journal:  Postgrad Med J       Date:  2006-05       Impact factor: 2.401

3.  Right axillary arterial perfusion for descending thoracic or thoracoabdominal aortic aneurysm repair with open proximal anastomosis through left thoracotomy.

Authors:  Nobuyoshi Kawaharada; Toshiro Ito; Shuichi Naraoka; Takayuki Hagiwara; Tetsuya Koyanagi; Yoshihiko Kurimoto; Tetsuya Higami
Journal:  Gen Thorac Cardiovasc Surg       Date:  2014-05-04

4.  Right Axillary Artery Cannulation in Aortic Valve Replacement.

Authors:  Mitsuharu Hosono; Toshihiko Shibata; Takashi Murakami; Masanori Sakaguchi; Yasuo Suehiro; Shigefumi Suehiro
Journal:  Ann Thorac Cardiovasc Surg       Date:  2016-01-15       Impact factor: 1.520

5.  Minimal access aortic root, valve, and complex ascending aortic surgery.

Authors:  J G Byrne; A N Karavas; L H Cohn; D H Adams
Journal:  Curr Cardiol Rep       Date:  2000-11       Impact factor: 2.931

6.  Direct cannulation of the common carotid artery during the ascending aortic or aortic arch replacement.

Authors:  Yukio Kuniyoshi; Kageharu Koja; Kazufumi Miyagi; Tooru Uezu; Satoshi Yamashiro; Katuya Arakaki; Katuhito Mabuni; Shigenobu Senaha
Journal:  Jpn J Thorac Cardiovasc Surg       Date:  2004-05

7.  Direct cannulation of the infrahepatic vena cava for emergent cardiopulmonary bypass support.

Authors:  Raja R Gopaldas; Kirti P Patel; James J Livesay; Denton A Cooley
Journal:  Tex Heart Inst J       Date:  2009

8.  Minimally-invasive cardiac surgery: a bibliometric analysis of impact and force to identify key and facilitating advanced training.

Authors:  Rickesh Bharat Karsan; Rhian Allen; Arfon Powell; Gwyn William Beattie
Journal:  J Cardiothorac Surg       Date:  2022-09-16       Impact factor: 1.522

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.